Related Experiment Video
Updated: Aug 17, 2026
Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
New drugs being developed for the treatment of tuberculosis
1School of Nursing, Auckland University of Technology--Akoranga Campus, Northcote, Auckland, New Zealand. s_doggrell@yahoo.com
Abstract:
More than one-third of the world is infected with tuberculosis (TB) and 5000 people die of TB everyday. Of the many diarylquinolones shown to be effective at inhibiting the multiple-cycle growth of Mycobacterium tuberculosis, R-207910 was the most active and was chosen as the lead compound. In the non-established infection mouse TB model, a single dose of R-207910 50 mg/kg had a bacteriostatic effect, and a bactericidal effect was observed at 100 mg/kg. In the established infection mouse model, treatment was started 12-14 days after infection, and when added to the triple therapy of isoniazid, rifampin and pyrazinamide or substituted for any component of the triple therapy, R-207910 increased the effectiveness. As ethambutol is chemically simple, and only has modest potency in treating TB, it was considered to be amenable to optimisation by combinatorial chemistry, and from the analogues synthesised that inhibited the growth of M. tuberculosis, SQ-109 was eventually selected as the lead compound for further testing. In female mice infected with M. tuberculosis H37Rv by tail-vein injection, treatment with SQ-109 25 mg p.o. initiated 20 days later for 5 days/week for 4 weeks reduced the counts by 1.87 log units, which was slightly more than with ethambutol 100 mg (1.67 log units). These results indicate that exciting new drugs are under development for the treatment of TB.
Insights
New tuberculosis (TB) drugs, R-207910 and SQ-109, show promise. These compounds effectively inhibit Mycobacterium tuberculosis growth and demonstrate therapeutic potential in preclinical TB models.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Tuberculosis (TB) remains a global health crisis, with high mortality rates.
- Existing treatments face challenges, necessitating the development of novel therapeutic agents.
- Diarylquinolones and ethambutol analogues are classes of compounds investigated for anti-TB activity.
Purpose of the Study:
- To evaluate the efficacy of novel compounds R-207910 and SQ-109 against Mycobacterium tuberculosis.
- To assess the therapeutic potential of these lead compounds in preclinical TB models.
Main Methods:
- R-207910, a diarylquinolone, was tested in non-established and established infection mouse TB models.
- SQ-109, an ethambutol analogue, was evaluated in a mouse model of M. tuberculosis H37Rv infection.
- Drug efficacy was assessed by measuring bacteriostatic and bactericidal effects, and reduction in bacterial counts.
Main Results:
- R-207910 exhibited bacteriostatic and bactericidal effects in mouse models and enhanced the efficacy of standard TB triple therapy.
- SQ-109 demonstrated potent activity, reducing bacterial counts more effectively than ethambutol in a mouse model.
- Both compounds showed significant potential in preclinical evaluations against M. tuberculosis.
Conclusions:
- R-207910 and SQ-109 represent promising lead compounds for the development of new anti-tuberculosis drugs.
- These findings highlight the ongoing progress in discovering novel therapeutic strategies to combat TB.
- Further development of these agents could offer new hope for patients suffering from this infectious disease.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: